Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Payables (2016 - 2025)

Protalix BioTherapeutics has reported Payables over the past 16 years, most recently at $5.3 million for Q4 2025.

  • Quarterly results put Payables at $5.3 million for Q4 2025, up 16.02% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (up 16.02% YoY), and the annual figure for FY2025 was $5.3 million, up 16.02%.
  • Payables for Q4 2025 was $5.3 million at Protalix BioTherapeutics, down from $5.4 million in the prior quarter.
  • Over the last five years, Payables for PLX hit a ceiling of $18.7 million in Q3 2023 and a floor of $3.1 million in Q3 2024.
  • Median Payables over the past 5 years was $5.6 million (2022), compared with a mean of $6.9 million.
  • Biggest five-year swings in Payables: crashed 83.27% in 2024 and later surged 71.45% in 2025.
  • Protalix BioTherapeutics' Payables stood at $16.4 million in 2021, then tumbled by 64.33% to $5.9 million in 2022, then dropped by 26.31% to $4.3 million in 2023, then rose by 4.93% to $4.5 million in 2024, then increased by 16.02% to $5.3 million in 2025.
  • The last three reported values for Payables were $5.3 million (Q4 2025), $5.4 million (Q3 2025), and $6.7 million (Q2 2025) per Business Quant data.